Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
The Journal of Allergy and Clinical Immunology: In Practice · 2023-09 · 11 (9) · 2732-2747
DOI: 10.1016/j.jaip.2023.05.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-09. Verfasst von Wenjia Chen und 59 weiteren Autor:innen. Beteiligte Einrichtung: Saw Swee Hock School of Public Health, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca, Optimum Patient Care, AstraZeneca UK Limited.
Abstract (Originalsprache)
BACKGROUND: Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone. OBJECTIVE: To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS. METHODS: This was a propensity score-matched, prospective cohort study using data from the International Severe Asthma Registry. Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCSs for ≥1 year or ≥4 courses of rescue OCSs within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with noninitiators. The impact of biologic initiation on asthma outcomes was assessed using generalized linear models. RESULTS: We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations per year versus noninitiators (0.64 vs 2.06; rate ratio, 0.27 [95% CI, 0.10-0.71]). Biologic initiators were 2.2 times more likely than noninitiators to take a daily long-term OCS dose of less than 5 mg (risk probability, 49.6% vs 22.5%; P = .002) and had a lower risk of asthma-related emergency department visits (relative risk, 0.35 [95% CI, 0.21-0.58]; rate ratio, 0.26 [0.14-0.48]) and hospitalizations (relative risk, 0.31 [95% CI, 0.18-0.52]; rate ratio, 0.25 [0.13-0.48]). CONCLUSIONS: In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and health care resource utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
- AstraZeneca, Gaithersburg, Md.
- Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
- Optimum Patient Care Global, Cambridge, United Kingdom.
- Optimum Patient Care Global, Cambridge, United Kingdom; Observational and Pragmatic Research Institute, Singapore.
- AstraZeneca, Barcelona, Spain.
Förderung
- AstraZeneca
- Optimum Patient Care
- AstraZeneca UK Limited
Zitieren
APA
Chen, W., Tran, T. N., Sadatsafavi, M., Murray, R., Wong, N. C. B., Ali, N., Ariti, C., Bulathsinhala, L., Gil, E. G., FitzGerald, J. M., Alacqua, M., Al-Ahmad, M., Altraja, A., Al-Lehebi, R., Bhutani, M., Bjermer, L., Bjerrum, A. S., Bourdin, A., von Bülow, A., …, & Torres-Duque, C. A. (2023). Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry. The Journal of Allergy and Clinical Immunology: In Practice, 11(9), 2732-2747. https://doi.org/10.1016/j.jaip.2023.05.044
Vancouver
Chen W, Tran TN, Sadatsafavi M, Murray R, Wong NCB, Ali N, et al. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(9):2732-2747. doi:10.1016/j.jaip.2023.05.044
BibTeX
@article{Chen2023,
author = {Chen, Wenjia and Tran, Trung N and Sadatsafavi, Mohsen and Murray, Ruth and Wong, Nigel Chong Boon and Ali, Nasloon and Ariti, Con and Bulathsinhala, Lakmini and Gil, Esther Garcia and FitzGerald, J Mark and Alacqua, Marianna and Al-Ahmad, Mona and Altraja, Alan and Al-Lehebi, Riyad and Bhutani, Mohit and Bjermer, Leif and Bjerrum, Anne-Sofie and Bourdin, Arnaud and von Bülow, Anna and Busby, John and Canonica, Giorgio Walter and Carter, Victoria and Christoff, George C and Cosio, Borja G and Costello, Richard W and Fonseca, João A and Gibson, Peter G and Yoo, Kwang-Ha and Heaney, Liam G and Heffler, Enrico and Hew, Mark and Hilberg, Ole and Hoyte, Flavia and Iwanaga, Takashi and Jackson, David J and Jones, Rupert C and Koh, Mariko Siyue and Kuna, Piotr and Larenas-Linnemann, Désirée and Lehmann, Sverre and Lehtimäki, Lauri and Lyu, Juntao and Mahboub, Bassam and Maspero, Jorge and Menzies-Gow, Andrew N and Newell, Anthony and Sirena, Concetta and Papadopoulos, Nikolaos G and Papaioannou, Andriana I and Perez-de-Llano, Luis and Perng Steve, Diahn-Warng and Peters, Matthew and Pfeffer, Paul E and Porsbjerg, Celeste M and Popov, Todor A and Rhee, Chin Kook and Salvi, Sundeep and Taillé, Camille and Taube, Christian and Torres-Duque, Carlos A},
title = {Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
volume = {11},
number = {9},
pages = {2732--2747},
doi = {10.1016/j.jaip.2023.05.044}
}
EUVIMED